title: Use of terbinafine for tinea in Australian Aboriginal communities in the Top End.
abstract: Tinea of the skin and nails is a common problem in remote Aboriginal communities of the Top End of Australia. A retrospective study was performed on data collected from 104 patients from several indigenous communities. Worksheets were filled in by district medical officers and rural general practitioners, detailing the extent of the tinea. Patients were prescribed between 4 and 12 weeks of 250 mg daily oral terbinafine. Fifty-two patients were followed up, with 45 having a good response to treatment (87%) and with 22 of these patients having full clearance of tinea (42%). A prospective study with 44 subjects was performed. The extent of the tinea was documented and fungal scrapings/clippings were taken. Forty subjects were recruited and given oral terbinafine (2-12 weeks depending on skin/nail involvement) or topical terbinafine if oral treatment was contraindicated. Twenty-five of the 40 (63%) subjects were reviewed. Twenty-three (92%) subjects that were followed up improved clinically, with 8/25 (32%) clearing completely. Twenty (80%) of followed-up patients complied fully with treatment. Terbinafine was found to be a well-tolerated and effective treatment of tinea of the skin and nails.
authors: Royal Darwin Hospital and Northern Territory Clinical School, Darwin, South Australia, Australia.
authors: Karen J
authors: KJ
authors: Koh
authors: Colin J
authors: CJ
authors: Parker
authors: David H
authors: DH
authors: Ellis
authors: Bert
authors: B
authors: Pruim
authors: Loyla
authors: L
authors: Leysley
authors: Bart J
authors: BJ
authors: Currie
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage*; D001315:Australia; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage*; D011446:Prospective Studies; D012189:Retrospective Studies; D012720:Severity of Illness Index; D000077291:Terbinafine; D014005:Tinea / Q000175:diagnosis / Q000188:drug therapy* / Q000208:ethnology*; D016896:Treatment Outcome; D000095283:Australian Aboriginal and Torres Strait Islander Peoples
chemical_list: D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine